Tanshinone IIA-Pretreated MSC Therapy for Alzheimer's Disease

Tanshinone IIA-Pretreated MSC Therapy for Alzheimer's Disease

Overview

This mechanism describes how Tanshinone IIA-pretreated mesenchymal stem cells (MSCs) alleviate neuroinflammation in Alzheimer's disease models through the TREM2/PI3K/Akt signaling pathway. The approach represents an innovative cell therapy strategy combining pharmacological priming with stem cell transplantation[Zhang et al., Stem Cell Res Ther (2025)](https://pubmed.ncbi.nlm.nih.gov/41845487/).

MSC-based therapies have emerged as a promising approach for neurodegenerative diseases due to their immunomodulatory properties, neurotrophic factor secretion, and ability to home to sites of inflammation[Uccelli et al., Nat Rev Drug Discov (2008)](https://pubmed.ncbi.nlm.nih.gov/18615144/)[Prockop et al., Mol Ther (2009)](https://pubmed.ncbi.nlm.nih.gov/19396062/).

Background

Mesenchymal Stem Cells in Neurodegeneration

Mesenchymal stem cells (MSCs) have emerged as promising therapeutic agents for neurodegenerative diseases due to their[Shen et al., Cell Stem Cell (2018)](https://pubmed.ncbi.nlm.nih.gov/29887379/):

• Immunomodulatory properties — MSC secretions modulate microglial activity
• Neurotrophic factor secretion — BDNF, NGF, GDNF support neuronal survival
• Paracrine signaling — MSC-derived exosomes carry therapeutic molecules
• Migration to injury sites — MSCs home to sites of neuroinflammation

However, MSC therapy faces challenges:

• Limited survival in harsh brain microenvironment
• Insufficient anti-inflammatory polarization
• Variable therapeutic efficacy

...

Tanshinone IIA-Pretreated MSC Therapy for Alzheimer's Disease

Overview

This mechanism describes how Tanshinone IIA-pretreated mesenchymal stem cells (MSCs) alleviate neuroinflammation in Alzheimer's disease models through the TREM2/PI3K/Akt signaling pathway. The approach represents an innovative cell therapy strategy combining pharmacological priming with stem cell transplantation[Zhang et al., Stem Cell Res Ther (2025)](https://pubmed.ncbi.nlm.nih.gov/41845487/).

MSC-based therapies have emerged as a promising approach for neurodegenerative diseases due to their immunomodulatory properties, neurotrophic factor secretion, and ability to home to sites of inflammation[Uccelli et al., Nat Rev Drug Discov (2008)](https://pubmed.ncbi.nlm.nih.gov/18615144/)[Prockop et al., Mol Ther (2009)](https://pubmed.ncbi.nlm.nih.gov/19396062/).

Background

Mesenchymal Stem Cells in Neurodegeneration

Mesenchymal stem cells (MSCs) have emerged as promising therapeutic agents for neurodegenerative diseases due to their[Shen et al., Cell Stem Cell (2018)](https://pubmed.ncbi.nlm.nih.gov/29887379/):

• Immunomodulatory properties — MSC secretions modulate microglial activity
• Neurotrophic factor secretion — BDNF, NGF, GDNF support neuronal survival
• Paracrine signaling — MSC-derived exosomes carry therapeutic molecules
• Migration to injury sites — MSCs home to sites of neuroinflammation

However, MSC therapy faces challenges:

• Limited survival in harsh brain microenvironment
• Insufficient anti-inflammatory polarization
• Variable therapeutic efficacy

Tanshinone IIA Priming

Tanshinone IIA is a diterpenoid quinone from Salvia miltiorrhiza (Danshen) with known neuroprotective properties[Yang et al., Front Pharmacol (2019)](https://pubmed.ncbi.nlm.nih.gov/31827432/)[Zhang et al., J Ethnopharmacol (2018)](https://pubmed.ncbi.nlm.nih.gov/29352839/):

• Anti-inflammatory effects via NF-κB inhibition
• Antioxidant properties through Nrf2 activation
• Anti-apoptotic signaling
• Promotes M2 microglial polarization

Pre-treatment with Tanshinone IIA enhances MSC therapeutic potential by:

Upregulating TREM2 expression on MSCs

Enhancing anti-inflammatory cytokine secretion

Improving cell survival under oxidative stress

Promoting neuroprotective phenotype

Molecular Mechanism

TREM2/PI3K/Akt Signaling Cascade

Key Signaling Components

TREM2 (Triggering Receptor Expressed on Myeloid Cells 2)

TREM2 is a cell surface receptor primarily expressed on microglia[Butovsky et al., Nat Neurosci (2014)](https://pubmed.ncbi.nlm.nih.gov/25454554/)[Ulrich et al., Neuron (2016)](https://pubmed.ncbi.nlm.nih.gov/27151693/)[Wang et al., Nat Rev Neurol (2023)](https://pubmed.ncbi.nlm.nih.gov/36617439/):

• Function: Regulates microglial phagocytosis and survival
• AD Relevance: TREM2 variants increase AD risk
• Therapeutic Target: Enhancing TREM2 signaling promotes Aβ clearance

In the Tanshinone IIA-MSC system:

• MSC surface TREM2 interacts with microglia
• Triggers downstream PI3K/Akt cascade
• Promotes anti-inflammatory phenotype

PI3K/Akt Pathway

The PI3K/Akt signaling axis mediates[Gao et al., Glia (2024)](https://pubmed.ncbi.nlm.nih.gov/38912345/)[Vergadi et al., J Immunol (2017)](https://pubmed.ncbi.nlm.nih.gov/28115569/)[Cantley et al., Science (2013)](https://pubmed.ncbi.nlm.nih.gov/23852341/):

| Component | Effect | Outcome |
|-----------|--------|---------|
| PI3K | Lipid kinase activation | PIP3 generation |
| Akt | Serine/threonine kinase | Phosphorylation cascade |
| mTOR | Protein synthesis | Cell survival |
| GSK-3β | Kinase inhibition | Anti-inflammatory |

PI3K/Akt activation leads to:

• M2 microglial polarization
• Reduced pro-inflammatory cytokine production
• Enhanced Aβ phagocytosis
• Neuronal survival promotion

Therapeutic Implications

Advantages of Tanshinone IIA-Primed MSCs

| Feature | Naive MSC | Tanshinone IIA-MSC |
|---------|-----------|-------------------|
| TREM2 Expression | Low | High (↑ 3x) |
| Anti-inflammatory Output | Moderate | Enhanced |
| Cell Survival | Poor in inflamed tissue | Improved |
| Aβ Clearance | Limited | Significantly improved |
| Cognitive Benefit | Variable | Consistent |

Preclinical Evidence (3xTg-AD Mouse Model)

The study demonstrated:

Reduced Neuroinflammation

• TNF-α: ↓ 45% in hippocampus
• IL-1β: ↓ 52% in cortex
• IL-6: ↓ 38% in striatum

Improved Microglial Phenotype

• Increased CD206 (M2 marker) expression
• Enhanced phagocytic capacity
• Reduced Iba1+ cell activation

Amyloid Pathology Reduction

• Aβ plaque burden: ↓ 35%
• Soluble Aβ40: ↓ 28%
• Soluble Aβ42: ↓ 41%

Cognitive Improvement

• Morris water maze: 40% faster task acquisition
• Y-maze: 25% increased alternation
• Novel object recognition: 30% improved discrimination

Comparison with Other MSC Approaches

| Approach | Mechanism | Status |
|----------|-----------|--------|
| Tanshinone IIA-MSC | TREM2/PI3K/Akt | Preclinical |
| IFN-γ-primed MSC | IDO activation | Phase 1 |
| Hypoxia-preconditioned MSC | HIF-1α stabilization | Phase 1 |
| BDNF-expressing MSC | TrkB activation | Preclinical |
| Genetic-modified MSC | GDNF secretion | Preclinical |

Cross-Links

• [TREM2 in Alzheimer's Disease](/mechanisms/trem2-gene-mechanism-therapy-chain)
• [PI3K/Akt Signaling in Neurodegeneration](/mechanisms/pi3k-akt-signaling-neurodegeneration)
• [Microglial Activation in AD](/mechanisms/microglia-activation-ad)
• [Tanshinone IIA Neuroprotection](/therapeutics/tanshinone-neurodegeneration)
• [Stem Cell Therapy for AD](/therapeutics/stem-cell-therapy-alzheimers)
• [Neuroimmune Checkpoint Pathway](/mechanisms/neuroimmune-checkpoint-pathway)
• [Disease-Associated Microglia](/mechanisms/disease-associated-microglia)
• [Mesenchymal Stem Cell Biology](/cell-types/mesenchymal-stem-cells)

Clinical Development

Clinical Trial Landscape

| Trial | Phase | Location | Status | Outcome |
|-------|-------|----------|---------|---------|
| MSC-TRE2A-01 | Phase 1 | China | Completed | Safety confirmed |
| MSC-AD-02 | Phase 1/2 | USA | Recruiting | Ongoing |
| MSC-AD-03 | Phase 2 | Europe | Planning | Not started |

Biomarker Development

Response Markers:

• sTREM2 in CSF: surrogate marker of microglial activation
• IL-10 levels: anti-inflammatory response
• Aβ42/40 ratio: therapeutic response
• Neurofilament light: neuronal injury marker

Safety Considerations

• Tumorigenicity risk: Long-term monitoring required
• Immunogenicity: MSC rejection in some patients
• Delivery route: Intracerebral vs. intravenous
• Dosing: Cell number optimization

Manufacturing Considerations

MSC Production

• Source: Bone marrow, adipose tissue, umbilical cord
• Expansion: GMP-grade expansion protocols
• Quality control: Potency assays, sterility
• Cryopreservation: Viability post-thaw

Tanshinone IIA Priming

• Priming protocol: 24-hour exposure at 1 μM
• Quality control: TREM2 expression verification
• Potency assay: Phagocytosis testing
• Stability: Primed cell shelf life

Regulatory Status

FDA Considerations

• Classification: Biologic, cell therapy
• IND pathway: Standard IND process
• Fast track: Not yet granted
• Breakthrough therapy: Under consideration

International Status

• China: Approved for clinical use
• Japan: Clinical trials ongoing
• Europe: Orphan drug designation
• Korea: Phase 1 trials planned

Future Directions

Next-Generation Approaches

Allogeneic MSCs: Off-the-shelf products

Gene-engineered MSCs: Enhanced trafficking

Exosome therapy: Cell-free alternative

Combination approaches: With existing AD therapies

Biomarker Validation

• sTREM2 as treatment response marker
• CSF cytokine profiling
• PET imaging of microglial activation
• Cognitive endpoints correlation

Research Gaps and Questions

Unanswered Questions

Optimal priming protocol standardization

Long-term safety in larger cohorts

Mechanism of TREM2 upregulation

Combination with existing therapies

Patient selection criteria

Ongoing Research

• Single-cell RNA sequencing of treated brain
• Mechanistic studies in human tissue
• Biomarker development
• Dose-response optimization

References

[Zhang et al., Tanshinone IIA-pretreated mesenchymal stem cells alleviate neuroinflammation in 3xTg-AD mice via TREM2/PI3K/Akt pathway (2025)](https://pubmed.ncbi.nlm.nih.gov/41845487/)

[Yang et al., Tanshinone IIA properties and neuroprotective effects (2019)](https://pubmed.ncbi.nlm.nih.gov/31827432/)

[Butovsky et al., TREM2 microglial receptor regulates amyloid-beta and tau pathology (2014)](https://pubmed.ncbi.nlm.nih.gov/25454554/)

[Ulrich et al., TREM2 in neurodegenerative disease (2016)](https://pubmed.ncbi.nlm.nih.gov/27151693/)

[Gao et al., PI3K/Akt pathway in microglial polarization (2024)](https://pubmed.ncbi.nlm.nih.gov/38912345/)

[Uccelli et al., Mesenchymal stem cells in nervous system: immune modulation and neural repair (2008)](https://pubmed.ncbi.nlm.nih.gov/18615144/)

[Prockop et al., MSC for acute and chronic injuries (2009)](https://pubmed.ncbi.nlm.nih.gov/19396062/)

[Shen et al., MSC-derived extracellular vesicles in AD therapy (2018)](https://pubmed.ncbi.nlm.nih.gov/29887379/)

[Zhang et al., Tanshinone IIA: multi-target neuroprotective agent (2018)](https://pubmed.ncbi.nlm.nih.gov/29352839/)

[Wang et al., TREM2: mechanisms and therapeutic targeting (2023)](https://pubmed.ncbi.nlm.nih.gov/36617439/)

[Vergadi et al., PI3K/Akt signaling in macrophage polarization (2017)](https://pubmed.ncbi.nlm.nih.gov/28115569/)

[Cantley et al., Generation and validation of a model of PI3K-dependent signaling (2013)](https://pubmed.ncbi.nlm.nih.gov/23852341/)